Table 2.
Summary of SST2A IHC immunoreactive cell percentage, staining intensity, and combined scores based on histopathologic diagnosis.
| Immunoreactive cell percentage score (Range: 0-4) | Staining intensity score (Range: 0-3) | Combined SST2A IHC score (Range: 0-12) | |
|---|---|---|---|
| Entire cohort (n=120) | 1.4 (± 1.5) | 1.4 (± 1.2) | 3.5 (± 4.1) |
| Meningioma (n=15) | 2.4 (± 1.2) | 2.2 (± 0.9) | 5.7 (± 3.4) |
| Embryonal tumors (n=55) | 2.3 (± 1.4) | 2.1 (± 1.0) | 5.8 (± 4.2) |
| • Medulloblastoma (n=38) | 2.9 (± 1.2) | 2.6 (± 0.6) | 7.5 (± 3.5) |
| • Pineoblastoma (n=4) | 1.5 (± 0.6) | 2.5 (± 0.4) | 3.8 (± 1.5) |
| • ATRT (n=3) | 0.3 (± 0.6) | 0.3 (± 0.6) | 0.3 (± 0.6) |
| • ETMR (n=3) | 1.0 (± 0.0) | 1.0 (± 0.0) | 1.0 (± 0.0) |
| • Other embryonal tumors (n=7) a | 0.8 (± 1.3) | 0.9 (± 1.2) | 2.0 (± 4.0) |
| Ependymoma (n=27) | 0.1 (± 0.3) | 0.2 (± 0.7) | 0.2 (± 0.7) |
| • Ependymoma, grade I-II (n=18) | 0.1 (± 0.2) | 0.2 (± 0.7) | 0.3 (± 0.8) |
| • Anaplastic ependymoma (n=9) | 0.2 (± 0.4) | 0.3 (± 0.7) | 0.1 (± 0.3) |
| High-grade glioma (n=23) | 0.3 (± 0.5) | 0.4 (± 0.7) | 0.4 (± 0.7) |
| • Grade III, anaplastic glioma (n=5)* | 0.0 (± 0.0) | 0.0 (± 0.0) | 0.0 (± 0.0) |
| • High-grade glioneuronal tumor (n=2) | 1.0 (± 0.0) | 1.0 (± 0.0) | 1.0 (± 0.0) |
| • Glioblastoma (n=9) | 0.7 (± 0.5) | 0.9 (± 0.8) | 0.9 (± 0.8) |
| • Diffuse midline glioma, H3K27M-mutant (non-pontine) (n=3) | 0.0 (± 0.0) | 0.0 (± 0.0) | 0.0 (± 0.0) |
| • DIPG (n=4)# | 0.0 (± 0.0) | 0.0 (± 0.0) | 0.0 (± 0.0) |
Scores are shown as mean (± SD) for the entire cohort and within respective histopathologic diagnosis subgroups.
The subgroup designated “other embryonal tumors” includes six patients with tumors formerly classified as CNS primitive neuro-ectodermal tumor (PNET) and one patient more recently diagnosed with embryonal tumor, not otherwise specified (NOS).
* Including tumors classified as anaplastic astrocytoma (n=3), anaplastic pleomorphic xanthoastrocytoma (n=1), and anaplastic oligodendroglioma (n=1).
# Including tumors diagnosed as DIPG on the basis of classic radiographic and clinical features, histologically consistent with diffuse midline glioma, H3K27M-mutant (n=3) and anaplastic astrocytoma (n=1) [all with tissue available from biopsy].